Summary:
Click image to enlargeGalderma is conducting a study of an investigational drug called nemolizumab for the treatment of Atopic Dermatitis/Eczema. The goal of the study is to evaluate the immune response to vaccinations for patients receiving the study drug.
Criteria:- Be 12-54 years old
- Have had Atopic Dermatitis/Eczema for at least 2 years
- Have Atopic Dermatitis/Eczema that covers at least 10% of your body
- Have used another Eczema treatment or cream in the last 6 months that didn’t fully treat your Eczema
- Be willing to receive two common approved vaccinations during study participation
- Subject willing to undergo treatment for 16 weeks
Qualified Participants May Receive:
Participants will receive all study-related visits, tests, common approved vaccines, and study drug or a placebo from a dedicated medical team at no cost. Volunteers who qualify to take part in the study will receive compensation for study-related travel.